

Ledipasvir-sofosbuvir for treating chronic hepatitis C

ERG Addendum 2

Produced by	School of Health and Related Research (ScHARR), The University of Sheffield
Correspondence to	Praveen Thokala, Research Fellow, ScHARR, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA
Date completed	17 th February 2015
Source of funding: This repo	ort was commissioned by the NIHR HTA Programme as project number

14/59/01.

Description of additional analyses undertaken by the ERG

Additional analyses were undertaken to exclude some comparators from the incremental analysis. The details of the comparators excluded and the reasons for their exclusion are as below:

- SMV+SOF excluded for all patients (reason: not established in current clinical practice)
- SOF+PEG-IFN2a+RBV excluded for GT4 non-cirrhotic patients (reason: not recommended in NICE guidance)
- SOF+RBV excluded for GT3 treatment experienced non-cirrhotic IFN-ineligible group (reason: not recommended in NICE guidance)

The analysis excluding these comparators was run for the following scenarios

- ERG base case
- Additional analysis 1: Alternative EMA-recommended treatment durations for LDV/SOF
- Additional analysis 2: Alternative transition probabilities based on the sofosbuvir
 STA model

It should be noted that the additional analyses 2 uses the ERG-preferred base case analysis as a starting point. All analyses were undertaken using point estimates of parameters due to the excessive computation time and complexity associated with running the probabilistic version of the model.

Table 1: Central estimates of cost-effectiveness (ERG-preferred base case)

(i) Genotype 1 treatment-naïve non-cirrhotic					
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER
LDV/SOF 12 weeks	17.20	£42,160.45	0.39	£8,843.83	£22,676
SOF+PEG-IFN2a+RBV	17.04	£41,081.62	ı	ı	ext dom
SMV+PEG-IFN2a+RBV	16.81	£33,316.62	0.85	£14,111.22	£16,601
TVR+PEG-IFN2a+RBV	16.69	£34,631.46	1	ı	dominated
BOC+PEG-IFN2b+RBV	16.41	£35,002.22	ı	ı	dominated
PEG-IFN2a+RBV	15.96	£19,205.40	0.89	£6175.99	£6,939
No treatment	15.07	£13,029.41	-	-	-
(ii) Genotype 1 treatment-na	ive cirrhoti	c			
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER
LDV/SOF 24 weeks	10.08	£101,051.95	0.83	£37,618.44	£45,323
SOF+PEG-IFN2a+RBV	9.25	£63,433.51	2.71	£15,167.91	£5,597
SMV+PEG-IFN2a+RBV	8.28	£59,097.68	ı	ı	ext dom
BOC+PEG-IFN2b+RBV	8.09	£64,985.45	-	-	dominated
TVR+PEG-IFN2a+RBV	7.95	£61,326.36	-		ext dom
PEG-IFN2a+RBV	6.54	£48,265.60	1.29	£7,012.58	£5,436
No treatment	5.25	£41,253.02	-	-	-

(iii) Genotype 4 treatment-naïve non-cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	17.20	£42,160.45	0.39	£8,843.83	£22,676	
SMV+PEG-IFN2a+RBV	16.81	£33,316.62	0.85	£14,111.22	£16,601	
PEG-IFN2a+RBV	15.96	£19,205.40	0.89	£6,175.99	£6,939	
No treatment	15.07	£13,029.41	- 0.07	20,173.77	20,737	
(iv) Genotype 4 treatment-na						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 24 weeks	10.08	£101,051.95	0.83	£37,618.44	£45,323	
SOF+PEG-IFN2a+RBV	9.25	£63,433.51	2.71	£15,167.91	£5,597	
SMV+PEG-IFN2a+RBV	8.28	£59,097.68	2.71	213,107.71	ext dom	
PEG-IFN2a+RBV	6.54	£48,265.60	1.29	£7,012.58	£5,436	
No treatment	5.25	£41,253.02	1.27	27,012.36	23,430	
(v) Genotype 1/4 treatment-e					_	
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	16.11	£41,978.77	1.80	£29,819.05	£16,566	
SOF+PEG-IFN2a+RBV*	15.71	£42,386.90	1.00	229,019.03	dominated	
SMV+PEG-IFN2a+RBV	15.67	£38,729.70		_	ext dom	
TVR+PEG-IFN2a+RBV*	15.62	£36,459.92		-	ext dom	
BOC+PEG-IFN2b+RBV*	15.48	£39,911.38	-	-	dominated	
PEG-IFN2a+RBV	13.48	£18,984.11	-	-	ext dom	
No treatment	14.01	£12,159.72	-	-	ext dolli	
(vi) Genotype 1/4 treatment-			-	_	-	
			Ina OALVa	Inc. costs	ICER	
Option LDV/SOF 24 weeks	QALYs 9.70	Costs £99,222.17	Inc. QALYs	Inc. costs		
SOF+PEG-IFN2a+RBV	8.59	·	3.4	£36,028.74	£32,458	
SMV+PEG-IFN2a+RBV	8.39	£63,193.43 £62,045.65	3.4	£22,542.63	£6,630 ext dom	
TVR+PEG-IFN2a+RBV*	7.46	·	-	-		
BOC+PEG-IFN2b+RBV*	6.95	£63,324.53	-	-	dominated	
		£68,413.45	-	-	dominated	
PEG-IFN2a+RBV No treatment	5.74 5.19	£47,441.22 £40,650.80	-	-	ext dom	
(vii) Genotype 3 treatment-n			-	-	-	
· / /			In a OAL Va	Tuo costo	ICED	
Option	QALYs			Inc. costs £71,970.90	ICER	
LDV/SOF+RBV 24 weeks	17.24		0.81	£/1,9/0.90	£88,853	
PEG-IFN2a+RBV	16.43	£11,359.86	-	-	ا معدند مدا	
No treatment	14.57	£14,928.01			dominated	
(viii) Genotype 3 treatment-			In a OAL Va	In a seets	ICED	
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	10.23	£102,644.92	0.85	£39,226.39	£46,149	
SOF+RBV SOF+PEG-IFN2a+RBV	9.87	£95,947.03	4 12	COO 165 51	ext dom	
	9.38	£63,418.53	4.13	£22,165.51	£2,363	
No treatment 5.25 £41,253.02						
(ix) Genotype 3 treatment-experienced IFN-ineligible non-cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	15.97	£84,108.64	2.09	£70,172.93	£33,576	
No treatment	13.88	£13,935.71			_	
(x) Genotype 3 treatment-experienced IFN-ineligible cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	8.76	£105,760.87	3.57	£65,110.07	£18,238	
SOF+RBV	8.01	£101,108.73	-	-	ext dom	
*not applicable for genotype 4 pati	5.19	£40,650.80	-	_	_	

*not applicable for genotype 4 patients Inc. – incremental; ICER – incremental cost-effectiveness ratio; ext dom – extended dominance; IFN – interferon

Table 2: Central estimates of cost-effectiveness (additional analysis 1, alternative EMArecommended LDV/SOF treatment durations)

(i) Genotype 1 treatment-naïve non-cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 8 weeks	17.12	£29,522.69	1.16	£10,317.29	£8,894	
SOF+PEG-IFN2a+RBV	17.04	£41,081.62	-	-	dominated	
SMV+PEG-IFN2a+RBV	16.81	£33,316.62	-	-	dominated	
TVR+PEG-IFN2a+RBV	16.69	£34,631.46	-	-	dominated	
BOC+PEG-IFN2b+RBV	16.41	£35,002.22	-	-	dominated	
PEG-IFN2a+RBV	15.96	£19,205.40	0.89	£6,175.99	£6,939	
No treatment	15.07	£13,029.41	-	-	-	
(ii) Genotype 1 treatment-na	ive cirrhoti	c				
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	9.94	£62,440.44	4.69	£21,187.42	£4,518	
SOF+PEG-IFN2a+RBV	9.25	£63,433.51	-	-	dominated	
SMV+PEG-IFN2a+RBV	8.28	£59,097.68	-	-	ext dom	
BOC+PEG-IFN2b+RBV	8.09	£64,985.45	-	-	dominated	
TVR+PEG-IFN2a+RBV	7.95	£61,326.36	-	-	ext dom	
PEG-IFN2a+RBV	6.54	£48,265.60	-	-	ext dom	
No treatment	5.25	£41,253.02	-	-	-	
(iii) Genotype 1/4 treatment-	experience	d non-cirrhotic				
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 24 weeks	16.21	£80,577.05	0.54	41847.35	£77,495	
SOF+PEG-IFN2a+RBV*	15.71	£42,386.90	-	-	ext dom	
SMV+PEG-IFN2a+RBV	15.67	£38,729.70	0.05	£2,269.78	£45,396	
TVR+PEG-IFN2a+RBV*	15.62	£36,459.92	1.31	£24,300.20	£18,550	
BOC+PEG-IFN2b+RBV*	15.48	£39,911.38	-	-	dominated	
PEG-IFN2a+RBV	14.61	£18,984.11	-	-	ext dom	
No treatment	14.31	£12,159.72	-	-	-	
(iv) Genotype 3 treatment-naive non-cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	17.24	£42,997.49	0.81	£31,637.63	£39,277	
PEG-IFN2a+RBV	16.43	£11,359.86	-	-	-	
No treatment	14.57	£14,928.01	-	_	dominated	

*not applicable for genotype 4 patients Inc. – incremental; ICER – incremental cost-effectiveness ratio; ext dom – extended dominance; IFN – interferon

Table 3: Central estimates of cost-effectiveness (additional analysis 2, use of alternative transition probabilities based on the sofosbuvir STA model)

(i) Genotype 1 treatment-naïve non-cirrhotic						
Option Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	17.20	£42,184.89	0.34	£8,678.81	£25,526	
SOF+PEG-IFN2a+RBV	17.06	£41,170.98	-	-	ext dom	
SMV+PEG-IFN2a+RBV	16.86	£33,506.08	0.75	£13,725.14	£18,300	
TVR+PEG-IFN2a+RBV	16.75	£34,867.92	_	_	dominated	
BOC+PEG-IFN2b+RBV	16.51	£35,371.57	_	_	dominated	
PEG-IFN2a+RBV	16.11	£19,780.94	0.75	£5,679.23	£7,572	
No treatment	15.36	£14,101.71	-	-	-	
(ii) Genotype 1 treatment-na						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 24 weeks	10.18	£102,305.63	0.45	£35,954.63	£79,899	
SOF+PEG-IFN2a+RBV	9.73	£66,351.00	1.46	£9,632.22	£6,597	
SMV+PEG-IFN2a+RBV	9.20	£64,023.82	-	-	ext dom	
BOC+PEG-IFN2b+RBV	9.12	£70,316.26	-	-	dominated	
TVR+PEG-IFN2a+RBV	9.03	£66,927.05	-	-	dominated	
PEG-IFN2a+RBV	8.27	£56,718.78	0.71	£4,268.64	£6,012	
No treatment	7.56	£52,450.14	-	_	-	
(iii) Genotype 4 treatment-ne	aïve non-cir	rrhotic				
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 12 weeks	17.20	£42,184.89	0.34	£8,678.81	£25,526	
SMV+PEG-IFN2a+RBV	16.86	£33,506.08	0.75	£13,725.14	£18,300	
PEG-IFN2a+RBV	16.11	£19,780.94	0.75	£5,679.23	£7,572	
No treatment	15.36	£14,101.71	-	-	-	
(iv) Genotype 4 treatment-na	iive cirrhot	ic				
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 24 weeks	10.18	£102,305.63	0.45	£35,954.63	£79,899	
SOF+PEG-IFN2a+RBV	9.73	£66,351.00	1.46	£9,632.22	£6,597	
SMV+PEG-IFN2a+RBV	9.20	£64,023.82	-	-	ext dom	
	7. - 0					
PEG-IFN2a+RBV	8.27	£56,718.78	0.71	£4,268.64	£6,012	
PEG-IFN2a+RBV No treatment		·	0.71	£4,268.64		
	8.27 7.56	£56,718.78 £52,450.14	0.71	£4,268.64		
No treatment	8.27 7.56	£56,718.78 £52,450.14	0.71 Inc. QALYs	£4,268.64 - Inc. costs		
No treatment (v) Genotype 1/4 treatment-e	8.27 7.56 experienced	£56,718.78 £52,450.14 non-cirrhotic Costs	Inc. QALYs	Inc. costs	£6,012	
No treatment (v) Genotype 1/4 treatment-e	8.27 7.56 experienced QALYs	£56,718.78 £52,450.14 Inon-cirrhotic Costs	Inc. QALYs	Inc. costs	£6,012 - ICER	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16	Inc. QALYs	Inc. costs	£6,012 - ICER £18,614	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV*	8.27 7.56 experienced QALYs 16.12 15.77	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76	Inc. QALYs	Inc. costs	ICER £18,614 dominated ext dom ext dom	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12 15.77 15.73	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81	Inc. QALYs 1.56	Inc. costs	ICER £18,614 dominated ext dom	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV*	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16	Inc. QALYs 1.56	Inc. costs £29,038.36	ICER £18,614 dominated ext dom ext dom	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81 14.56	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80	Inc. QALYs 1.56	Inc. costs £29,038.36	ICER £18,614 dominated ext dom ext dom dominated	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment-	8.27 7.56 experienced QALYs 16.12 15.77 15.68 15.57 14.81 14.56 experienced	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 In cirrhotic	Inc. QALYs 1.56	Inc. costs £29,038.36	ICER \$18,614 dominated ext dom ext dom dominated ext dom -	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment- Option	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81 14.56 experienced QALYs	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 Icirrhotic Costs	Inc. QALYs 1.56 Inc. QALYs	Inc. costs £29,038.36 Inc. costs	ICER \$18,614 dominated ext dom ext dom dominated ext dom - ICER	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment- Option LDV/SOF 24 weeks	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81 14.56 experienced QALYs 9.78	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 Icirrhotic Costs £100,330.45	Inc. QALYs 1.56 Inc. QALYs 0.59	Inc. costs £29,038.36 Inc. costs £33,857.41	ICER £18,614 dominated ext dom ext dom dominated ext dom ICER £57,385	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment- Option LDV/SOF 24 weeks SOF+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12 15.77 15.68 15.57 14.81 14.56 experienced QALYs 9.78 9.19	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 I cirrhotic Costs £100,330.45 £66,473.04	Inc. QALYs 1.56 Inc. QALYs	Inc. costs £29,038.36 Inc. costs	£6,012 - ICER £18,614 dominated ext dom ext dom dominated ext dom - ICER £57,385 £8,660	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment- Option LDV/SOF 24 weeks SOF+PEG-IFN2a+RBV SMV+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81 14.56 experienced QALYs 9.78 9.19 9.03	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 Indicirrhotic Costs £100,330.45 £66,473.04 £65,803.66	Inc. QALYs 1.56 Inc. QALYs 0.59	Inc. costs £29,038.36 Inc. costs £33,857.41	£6,012 - ICER £18,614 dominated ext dom dominated ext dom - ICER £57,385 £8,660 ext dom	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment-Option LDV/SOF 24 weeks SOF+PEG-IFN2a+RBV SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12 15.77 15.68 15.57 14.81 14.56 experienced QALYs 9.78 9.19 9.03 8.59	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 d cirrhotic Costs £100,330.45 £66,473.04 £65,803.66 £68,854.52	Inc. QALYs 1.56 Inc. QALYs 0.59 1.81	Inc. costs £29,038.36 Inc. costs £33,857.41	ICER \$18,614 dominated ext dom ext dom dominated ext dom ICER \$57,385 \$8,660 ext dom dominated	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment- Option LDV/SOF 24 weeks SOF+PEG-IFN2a+RBV SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV BOC+PEG-IFN2b+RBV*	8.27 7.56 experienced QALYs 16.12 15.77 15.73 15.68 15.57 14.81 14.56 experienced QALYs 9.78 9.19 9.03 8.59 8.33	£56,718.78 £52,450.14 Inon-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 Indicirrhotic Costs £100,330.45 £66,473.04 £65,803.66 £68,854.52 £74,964.16	Inc. QALYs 1.56 Inc. QALYs 0.59 1.81	Inc. costs £29,038.36 Inc. costs £33,857.41 £15,676.01	ICER £18,614 dominated ext dom ext dom dominated ext dom ICER £57,385 £8,660 ext dom dominated dominated	
No treatment (v) Genotype 1/4 treatment-e Option LDV/SOF12 weeks SOF+PEG-IFN2a+RBV* SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV* BOC+PEG-IFN2b+RBV* PEG-IFN2a+RBV No treatment (vi) Genotype 1/4 treatment-Option LDV/SOF 24 weeks SOF+PEG-IFN2a+RBV SMV+PEG-IFN2a+RBV TVR+PEG-IFN2a+RBV	8.27 7.56 experienced QALYs 16.12 15.77 15.68 15.57 14.81 14.56 experienced QALYs 9.78 9.19 9.03 8.59	£56,718.78 £52,450.14 non-cirrhotic Costs £42,032.16 £42,603.76 £38,911.81 £36,678.99 £40,189.27 £19,643.16 £12,993.80 d cirrhotic Costs £100,330.45 £66,473.04 £65,803.66 £68,854.52	Inc. QALYs 1.56 Inc. QALYs 0.59 1.81	Inc. costs £29,038.36 Inc. costs £33,857.41 £15,676.01	ICER \$18,614 dominated ext dom ext dom dominated ext dom ICER \$57,385 \$8,660 ext dom dominated	

(vii) Genotype 3 treatment-naïve non-cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF 24 weeks	17.24	£83,330.76	0.7	£71,547.68	£102,210	
PEG-IFN2a+RBV	16.54	£11,783.08	ı	ı	-	
No treatment	14.97	£16,429.60	1	-	dominated	
(viii) Genotype 3 treatment-r	aïve cirrho	otic				
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	10.26	£103,591.07	0.47	£37,517.89	£79,825	
SOF+RBV	10.08	£97,657.23	ı	ı	ext dom	
SOF+PEG-IFN2a+RBV	9.79	£66,073.18	2.23	£13,623.04	£1,392	
No treatment	7.56	£52,450.14	ı	ı	-	
(ix) Genotype 3 treatment-ex	perienced l	IFN-ineligible no	on-cirrhotic			
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	16.01	£84,234.47	1.78	£69,124.36	£38,834	
No treatment	14.23	£15,110.11	ı	ı	-	
(x) Genotype 3 treatment-experienced IFN-ineligible cirrhotic						
Option	QALYs	Costs	Inc. QALYs	Inc. costs	ICER	
LDV/SOF+RBV 24 weeks	9.28	£108,736.80	1.9	£57,939.77	£30,495	
SOF+RBV	8.89	£105,607.67	-	-	ext dom	
No treatment	7.38	£50,797.03	-	_	-	

*not applicable for genotype 4 patients Inc. – incremental; ICER – incremental cost-effectiveness ratio; ext dom – extended dominance; IFN – interferon